News & Pipeline

The latest on new drugs, approvals, and regulation across the GLP-1 space.

5 articles in this category.

Start here

Choose the question you want to answer first.

Looking for your state? Browse state coverage guides
Two smooth grey river stones of different sizes resting side by side on a folded linen cloth in soft morning light
AnalysisNews & Pipeline

Saxenda Is Being Discontinued in January 2027: What Is Actually Ending, and What Switching Really Costs You

Yes. Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027, and says the decision is not about safety or quality. Victoza stays on the market, and so do the Hikma, Meitheal and Teva-distributed generic liraglutide lines. The US prescribing information we reviewed for Saxenda, Wegovy and Zepbound does not provide a dose conversion from Saxenda to Wegovy or Zepbound, so plan any switch with your prescriber.

August 27, 2026

10 min read

An open folder of blank paper on a wooden desk.
NewsNews & Pipeline

FDA Proposes 503B Bulk-Compounding Exclusions for Semaglutide, Tirzepatide & Liraglutide

FDA's May 2026 notice proposed not including semaglutide, tirzepatide and liraglutide on the 503B clinical-need bulks list. The comment period closed July 30. That notice is not a final determination, does not eliminate the separate drug-shortage route and does not decide whether an individual 503A prescription meets the law.

May 8, 2026

8 min read

Ready to pick a provider? Take the 60-second match quiz or browse our full GLP-1 provider rankings.

Featured Partners

Affiliate partners we feature. We may earn a commission.

Embody

Embody illustration of a compounded semaglutide injection vial
from $49/mo·Compounded

Collective

Collective provider illustration of compounded semaglutide injection vial
from $59/mo + $199/year membership after 21 days·Compounded

Gala

Current program options·Brand & Compounded

Check the medication, commitment and total price for your selected plan.

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.